On April 30, 2025 Mabqi reported that Sylvain Yon, CEO, will be attending BioEquity Europe 2025, Europe’s leading international event connecting biopharma leaders and financial dealmakers with emerging biotech innovators (Press release, Mabqi, APR 30, 2025, View Source [SID1234652389]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will take place from May 12 to 14, 2025, at the Bruges Meeting & Convention Center (BMCC) in Belgium, followed by two days of virtual partnering on May 20 and 21, 2025.

During this key industry meeting, Mabqi will showcase the latest preclinical results of lead candidate MQI-201 and growing portfolio of first-in-class and best-in-class proprietary functional antibodies, including pH-sensitive antibodies and antibody-drug conjugates (ADCs) with strong therapeutic potential in oncology.

"BioEquity Europe offers a unique platform to highlight our innovation, engage with potential partners, and enhance Mabqi’s visibility within the global biotech and investor community."